Spadin as a new antidepressant: absence of TREK-1-related side effects.
about
A human TREK-1/HEK cell line: a highly efficient screening tool for drug development in neurological diseasesGlia-derived ATP inversely regulates excitability of pyramidal and CCK-positive neurons.Targeting two-pore domain K(+) channels TREK-1 and TASK-3 for the treatment of depression: a new therapeutic concept.Retroinverso analogs of spadin display increased antidepressant effectsIn vitro and in vivo regulation of synaptogenesis by the novel antidepressant spadin.Behavioral characterization of mice lacking Trek channels.Fluoxetine Protection in Decompression Sickness in Mice is Enhanced by Blocking TREK-1 Potassium Channel with the "spadin" Antidepressant.Formation of Functional Heterodimers by TREK-1 and TREK-2 Two-pore Domain Potassium Channel Subunits.Potentiation of Calcium Influx and Insulin Secretion in Pancreatic Beta Cell by the Specific TREK-1 Blocker Spadin.TREK-king the blood-brain-barrier.The role of two-pore-domain background K⁺ (K₂p) channels in the thalamus.The CNS under pathophysiologic attack--examining the role of K₂p channels.The family of K2P channels: salient structural and functional properties.Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity.Relative contribution of SKCa and TREK1 channels in purinergic and nitrergic neuromuscular transmission in the rat colon.The peptidic antidepressant spadin interacts with prefrontal 5-HT(4) and mGluR(2) receptors in the control of serotonergic function.Isoflurane exposure regulates the cell viability and BDNF expression of astrocytes via upregulation of TREK‑1.The Role of the Two-Pore Domain Potassium Channel TREK-1 in the Therapeutic Effects of Escitalopram in a Rat Model of Poststroke Depression.Muscarinic modulation of TREK currents in mouse sympathetic superior cervical ganglion neurons.Differential phospholipase C-dependent modulation of TASK and TREK two-pore domain K+ channels in rat thalamocortical relay neurons.Acetylcholine-dependent upregulation of TASK-1 channels in thalamic interneurons by a smooth muscle-like signalling pathway.TREK-1 Channel Expression in Smooth Muscle as a Target for Regulating Murine Intestinal Contractility: Therapeutic Implications for Motility Disorders.Activation of TREK currents by riluzole in three subgroups of cultured mouse nodose ganglion neurons.Identification and characterization of two zebrafish Twik related potassium channels, Kcnk2a and Kcnk2b
P2860
Q28477495-6020B358-0308-41DE-950F-499C10D0D585Q30837319-42EB842B-659C-4895-9FF3-50BFCDDA5042Q34994509-8C6980D9-D2C0-4A6D-878B-53802C6EFF82Q34996777-59F1B236-8EB9-4368-9864-C9A44E30E651Q35538532-E5D37F3B-E2AE-4C8F-A7DF-C3805D63AE1AQ36213793-086B1B7C-DA20-41EE-86DA-4F47A628672EQ36584329-77A14088-8D94-4E98-B1A7-CDF470754C67Q37034414-09CFA875-28D0-4950-9466-B215E024831CQ37571762-918D8C44-BDC1-42A3-B317-19164DB0B780Q38190042-FE64533F-A830-4E36-AC97-A1B0E2B46D04Q38262854-4DD6CFE3-7E72-419E-92C8-BB4FD354CAF0Q38284426-79252E4D-5451-4B07-BEE0-E56CD1B827A9Q38296300-A131BDA6-0996-4E60-8D9D-3BDBC19C25D7Q41684438-CF9DFD35-C058-486E-B448-05BA63064A34Q42507072-5BD1FA4E-977C-4A05-B976-FA0B47A944AFQ46689873-AFD3EB6D-4253-41D5-A30C-DFAA74E0856EQ47248747-3E744F0B-B84C-4D80-8DDE-4886CC8E5019Q47677494-1114D0EA-FD11-48AB-BA93-FAC3CE607F19Q47717024-D28AB8FE-9D3B-4FAC-92C4-BD08D2A7E120Q47736726-0D276D1E-1BD1-41FF-826F-8B786E60F648Q48118510-23AEB25E-DBE8-4633-816B-96E982D4BF1EQ52689982-AECEA9E0-8247-4D5C-B029-C0C4DCA5DAB5Q55439672-A3CBEF9E-93DD-4D92-9775-36388F657389Q58548811-871306D7-4091-49D2-AD03-0FEBE2399B6A
P2860
Spadin as a new antidepressant: absence of TREK-1-related side effects.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Spadin as a new antidepressant: absence of TREK-1-related side effects.
@en
Spadin as a new antidepressant: absence of TREK-1-related side effects.
@nl
type
label
Spadin as a new antidepressant: absence of TREK-1-related side effects.
@en
Spadin as a new antidepressant: absence of TREK-1-related side effects.
@nl
prefLabel
Spadin as a new antidepressant: absence of TREK-1-related side effects.
@en
Spadin as a new antidepressant: absence of TREK-1-related side effects.
@nl
P2093
P50
P1433
P1476
Spadin as a new antidepressant: absence of TREK-1-related side effects
@en
P2093
P304
P356
10.1016/J.NEUROPHARM.2011.07.019
P577
2011-07-22T00:00:00Z